Coldstream Capital Management Inc. Sells 35 Shares of Gilead Sciences, Inc. (GILD)

Coldstream Capital Management Inc. cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.5% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,379 shares of the biopharmaceutical company’s stock after selling 35 shares during the quarter. Coldstream Capital Management Inc.’s holdings in Gilead Sciences were worth $452,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Contrarius Investment Management Ltd raised its stake in shares of Gilead Sciences by 2,630.1% in the first quarter. Contrarius Investment Management Ltd now owns 904,865 shares of the biopharmaceutical company’s stock worth $61,458,000 after purchasing an additional 871,721 shares during the last quarter. Heritage Trust Co purchased a new position in shares of Gilead Sciences in the first quarter worth about $3,589,000. Pitcairn Co. raised its stake in shares of Gilead Sciences by 37.1% in the first quarter. Pitcairn Co. now owns 19,231 shares of the biopharmaceutical company’s stock worth $1,306,000 after purchasing an additional 5,207 shares during the last quarter. Bienville Capital Management LLC purchased a new position in shares of Gilead Sciences in the first quarter worth about $570,000. Finally, Norinchukin Bank The raised its stake in shares of Gilead Sciences by 4.2% in the first quarter. Norinchukin Bank The now owns 174,400 shares of the biopharmaceutical company’s stock worth $11,845,000 after purchasing an additional 7,070 shares during the last quarter. Institutional investors own 76.23% of the company’s stock.

Several research analysts recently weighed in on the company. Argus upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price target for the company in a research report on Thursday, August 31st. Deutsche Bank reiterated a “buy” rating and set a $81.00 price target on shares of Gilead Sciences in a research report on Thursday, August 31st. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price target for the company in a research report on Friday, October 13th. Credit Suisse Group reiterated an “outperform” rating and set a $85.00 price target (up from $79.00) on shares of Gilead Sciences in a research report on Tuesday, August 29th. Finally, Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research report on Monday, August 28th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $85.11.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $75.88 on Tuesday. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. The stock has a market capitalization of $96,951.29, a P/E ratio of 7.75, a PEG ratio of -1.24 and a beta of 1.13. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business’s revenue was down 13.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.75 earnings per share. research analysts predict that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.74%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is presently 23.69%.

In other Gilead Sciences news, EVP Gregg H. Alton sold 25,000 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $82.65, for a total transaction of $2,066,250.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. Insiders sold 494,999 shares of company stock worth $37,404,139 over the last ninety days. Corporate insiders own 1.30% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://transcriptdaily.com/2017/12/12/coldstream-capital-management-inc-sells-35-shares-of-gilead-sciences-inc-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply